Endometrial Cancer

276

Review clinical trials related to Endometrial Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian and endometrial cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: Elizabeth Stover, MD, PhDUpdated: Nov 13, 2026Locations: 3
Eligibility criteria

Participants must have histologically confirmed relapsed or refractory ovarian c... [+26]

Prior treatment with any BCL-XL inhibitor, such as navitoclax. [+16]

Status: Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC

Participants needed: 393
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Canadian Cancer Trials GroupUpdated: Nov 12, 2026Locations: 124
Eligibility criteria

Patients must have had surgery consisting of hysterectomy and bilateral salpingo... [+8]

Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis. [+5]

Status: Recruiting

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).

Participants needed: 100
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: University of ChicagoUpdated: Nov 12, 2026Locations: 5
Eligibility criteria

Diagnosis of primary cervical cancer or uterine cancer of any histology [+6]

Distant metastases as determined clinically or radiographically based upon stand... [+5]

Status: Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \[or docetaxel, if participants cannot take paclitaxel\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs). In Cohort 2, the main goal is to assess how well BNT323 works by determining the objective response rate (ORR), that is, the percentage of participants whose tumor shrinks (partial response) or disappears (complete response) after treatment. The safety of BNT323 will also be assessed by following the occurrence of unfavorable/adverse effects that are seen after treatment. Other measures include the pharmacokinetics of BNT323 (or how BNT323 moves through and out of the body), the body's immune response, and the impact on quality of life.

Participants needed: 480
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: BioNTech SEUpdated: Nov 10, 2026Locations: 214
Eligibility criteria

Are female adults (defined as ≥18 years of age or acceptable age according to lo... [+9]

Are ineligible for all options in the investigator's choice of chemotherapy arm,... [+12]

Status: Recruiting

A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: Outpace Bio, Inc.Updated: Nov 12, 2026Locations: 5
Eligibility criteria

Age ≥ 18 years of age at the time of signing the informed consent form. [+9]

Women of child-bearing potential who are pregnant or breastfeeding. [+9]

Status: Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

Participants needed: 1,123
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Merck Sharp & Dohme LLCUpdated: Nov 10, 2026Locations: 271
Eligibility criteria

Has a histologically confirmed diagnosis of primary advanced or recurrent endome... [+2]

Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stro... [+7]

Status: Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).

Participants needed: 156
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Context Therapeutics Inc.Updated: Nov 10, 2026Locations: 16
Eligibility criteria

Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced... [+3]

Evidence of central nervous system metastases, leptomeningeal disease or spinal... [+2]

Status: Recruiting

Improving Rural Endometrial Cancer Care

This is a pilot feasibility study to enable intensive outreach for marginalized patients with endometrial cancer (EC). Rural residents as well as patients who self-identify as Black or African American patients with EC have higher mortality rates. This study aims to introduce a treatment focused patient navigation intervention for marginalized patients with EC to address the multiple barriers these patients face. Patient navigation is a personalized program to help patients navigate the health care system and access medical and non-medical services. For example, patient navigators can provide services such as mediating/facilitating communication between patients and their providers/health care team, advocating for patient needs, identifying financial assistance and insurance-related resources, coordinating complex patient care, and providing patients with psychosocial support. This study will assess the implementation and effectiveness of a navigation intervention targeting multilevel barriers to care. The primary objective is to evaluate the fidelity of following the patient navigation intervention protocol.

Participants needed: 50
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: UNC Lineberger Comprehensive Cancer CenterUpdated: Nov 10, 2026Locations: 1
Eligibility criteria

Written informed consent obtained to participate in the study and HIPAA authoriz... [+4]

Patients who are not receiving treatment within the UNC health care system [+1]

Status: Recruiting

Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunotherapy (anti-PD1 agent therapy; pembrolizumab or dostarlimab) is non-inferior to two years of maintenance therapy for patients with advanced/metastatic or recurrent endometrial cancer who have completed the standard course of cytotoxic chemotherapy plus anti-PD1 therapy (chemoimmunotherapy). Our hypothesis is that one year of maintenance therapy will be comparable, or statistically non-inferior, to two years of therapy. This question has clinical importance as there is not a clear optimal duration for maintenance immunotherapy in this setting, and checkpoint inhibitors are associated with their own unique toxicity profile (immune-related adverse events) and incremental costs to patients and the healthcare system at large. Patients who respond favorably to primary therapy and choose to enroll will be randomized (1:1) after completion of chemoimmunotherapy to one-year of maintenance anti-PD1 therapy (1-year arm) or to two-years of maintenance anti-PD1 therapy (2-year arm). The primary endpoint is progression-free survival (PFS) determined over the course of at least 3 years from randomization of patient follow up. Secondary endpoints are overall survival (OS) and incidence of immune-related adverse events (irAE). Finally, exploratory objectives include measuring differences in gut and vaginal microbial profiles and innate immune system (IIS) tumor profiles and correlation with clinical outcomes (PFS, OS).

Participants needed: 140
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: UNC Lineberger Comprehensive Cancer CenterUpdated: Nov 5, 2026Locations: 6
Eligibility criteria

Age ≥ 18 years at the time of consent. [+3]

Tumors with unknown mismatch repair protein status. [+1]

Status: Recruiting

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Background: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes. Objective: To test 2 study drugs-a vaccine that targets HER2 (AdHER2DC) plus a drug that supercharges immune cells that kill tumor cells (N-803)-combined with 2 FDA-approved cancer treatment drugs in people with EC. Eligibility: Adults aged 18 and older with HER2-positive EC that returned or got worse after treatment. Design: AdHER2DC vaccine is made from each participant s own blood. Participants will undergo apheresis: Blood is removed from the body through a tube attached to a needle. The blood passes through a machine that separates out the target cells. The remaining blood is returned to the body through a second needle. A special catheter may be needed. The first treatment cycle is 28 days; each cycle after that will be 21 days. All participants will get the 2 approved drugs and the vaccine. One drug is a tablet taken by mouth once a day, every day. The other drug is given through a tube attached to a needle inserted into a vein. The vaccine is injected under the skin. Participants will receive the vaccine on day 1 of cycles 1, 2, and 3. Additional doses up to 3 doses will be give if possible. Some participants will receive N-803. This drug is injected under the skin of the abdomen on day 1 of each cycle. Treatment may last up to 1 year. Follow-up visits will continue up to 2 more years.

Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18-120Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Nov 5, 2026Locations: 1
Eligibility criteria

Histologically confirmed endometrial cancer. [+19]

Administration of any standard of care or investigational checkpoint inhibitors... [+22]

Status: Recruiting

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.

Participants needed: 3,110
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Mayo ClinicUpdated: Nov 5, 2026Locations: 25
Eligibility criteria

Abnormal uterine bleeding [+3]

Prior hysterectomy [+80]

Status: Recruiting

Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers

The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.

Participants needed: 730
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Universiteit AntwerpenUpdated: Nov 6, 2026Locations: 1
Eligibility criteria

Individuals having female genital organs, regardless of their gender identity. [+5]

Individuals that underwent hysterectomy or ovariectomy. [+7]

Status: Not yet recruiting

Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers

This study aims to investigate the role of the gut microbiota and its derived factors, including bacterial-associated antigens that mimic tumor-associated antigens, in predicting response to immune checkpoint inhibitor immunotherapies in patients with various types of cancer. The aim is to explore whether gut microbiota-mediated immunological modulation is specific to the tumor being treated and whether it can be used to enhance antitumor response.

Participants needed: 360
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: European Institute of OncologyUpdated: Nov 4, 2026Locations: 1
Eligibility criteria

Histologically or cytologically confirmed disease (see 3.1) [+13]

Previous chemotherapy (< 28 days washout), radiation therapy, immunotherapy, or... [+20]

Status: Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (50:50) chance of getting either Rina-S or a chemotherapy agent as treatment in this study. The study duration will be approximately 3 years. The treatment duration will be different for every participant, but an average of 4 to 6 months is expected. All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s).

Participants needed: 660
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: GenmabUpdated: Nov 3, 2026Locations: 178
Eligibility criteria

Participants must have histologically or cytologically confirmed recurrent or pr... [+7]

Prior therapy with an antibody-drug conjugate containing a topoisomerase 1 inhib... [+3]

Status: Recruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.

Participants needed: 104
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Alliance for Clinical Trials in OncologyUpdated: Nov 4, 2026Locations: 30
Eligibility criteria

REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologicall... [+15]

Status: Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Nov 4, 2026Locations: 42
Eligibility criteria

Is at least 18 years of age inclusive at the time of signing the informed consen... [+12]

Has known or suspected leptomeningeal disease and/or untreated brain metastasis. [+17]

Status: Recruiting

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

Participants needed: 130
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sairopa B.V.Updated: Nov 3, 2026Locations: 11
Eligibility criteria

Male or female aged ≥18 years [+6]

Escalation Phase: Patients that suffer from melanoma, brain tumors, glioblastoma... [+19]

Status: Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Participants needed: 952
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GenmabUpdated: Nov 4, 2026Locations: 67
Eligibility criteria

Histologically or cytologically confirmed metastatic or unresectable solid malig... [+34]

History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that req... [+1]

Status: Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.

Participants needed: 7,000
Trial details
Age: 40+Biological sex: AllType: ObservationalSponsor: Adela, IncUpdated: Nov 4, 2026Locations: 17
Eligibility criteria

Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagno... [+2]

Currently receiving any treatment for cancer [+12]

Status: Recruiting

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.

Participants needed: 212
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Nov 4, 2026Locations: 10
Eligibility criteria

Willing and able to provide written informed consent for the trial. [+28]

Presence of metastatic or recurrent disease [+17]

Status: Not yet recruiting

Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With Endometrial Cancer

This Clinical trial will compare ICG cervical superficial injections versus superficial and deep injection for sentinel lymph node mapping in early-stage endometrial cancer patients

Participants needed: 200
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Barretos Cancer HospitalUpdated: Nov 4, 2026
Eligibility criteria

Women aged ≥18 years with a confirmed diagnosis of stage I endometrial cancer wh...

Allergic reaction of ICG and Iodo [+2]

Status: Recruiting

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. Our bodies have a built-in DNA "spell-checker," called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer. Participants must meet key criteria, including: * Women who are 18 years or older, and not pregnant at the time of joining the study * pMMR endometrial cancer only * Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent (with or without measurable disease) endometrial cancer * Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse * Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles. Experimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles). Control Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles). The study will include regular visits for: * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments. * Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: PfizerUpdated: Oct 30, 2026Locations: 54
Eligibility criteria

Women ≥18 years of age who are confirmed not pregnant at screening. [+8]

Prior systemic therapy for first-line advanced or recurrent endometrial cancer. [+10]

Status: Recruiting

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

Participants needed: 63
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Regor Pharmaceuticals Inc.Updated: Nov 2, 2026Locations: 6
Eligibility criteria

Adults with metastatic or locally advanced, unresectable solid tumors that have... [+4]

Diabetes mellitus requiring anti-hyperglycemic medication. [+5]

Status: Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Participants needed: 160
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: Oct 30, 2026Locations: 45
Eligibility criteria

is ≥ 18 years of age at the time of signing the informed consent. [+6]

has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer the... [+10]

Status: Recruiting

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.

Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Radiopharm Theranostics, LtdUpdated: Nov 2, 2026Locations: 6
Eligibility criteria

Adult participants ≥ 18 years of age. [+10]

History of prior organ transplant. [+22]